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ABSTRACT 
Less than 50% of malignant mesothelioma patients respond to standard chemotherapy 
treatment and there is a great need to identify these patients, and find their best 
treatment options. The aim of this thesis was to increase the understanding of drug 
sensitivity in malignant pleural mesothelioma. 
 
We studied six mesothelioma cell lines with different phenotype and growth 
characteristics. The apoptosis signaling mechanism after treatment with selenite was 
evaluated in two of the cell lines. The drug sensitivity to selenite, bortezomib and four 
conventional drugs, together with their expression of potential predictive markers was 
evaluated in all six cell lines with WST-1 and immunocytochemistry. We followed the 
development of resistance to pemetrexed and carboplatin treatment in a patient with a 
genome-wide analysis as well as studying specific proteins through silencing, 
immunohistochemistry and measuring serum levels in the patient. Pleural effusions 
containing primary malignant mesothelioma cells were received from 18 patients and 
we characterized and tested their sensitivity to 32 different drugs in a robotized ex vivo 
assay. Primary cells were further characterized by immunocytochemistry to evaluate 
the amount of malignant cells and to study the RRM1 and ERCC1 reactivity. 
 
The apoptosis and loss of mitochondrial membrane potential induced by selenite 
treatment was described and presents a complex signaling pattern. In samples from the 
drug resistant patient we observed that genes involved in the metabolic processes of 
pyrimidine and purine were upregulated and immunorectivity of EMA and cytokeratin 
7 was increased at resistance. Silencing of NT5C gene did not induce pemetrexed 
sensitivity in cell lines and levels of serum mesothelin related protein and carcinoma 
antigen 125 in serum correlated to the tumor burden. 
 
Selenite affected four out of six mesothelioma cell lines, and was in combination with 
bortezomib cytotoxic to all six. Epithelioid cells were more sensitive to the different 
drug and drug combinations than the sarcomatoid cells. Pemetrexed induced an 
extensive S-phase arrest in affected cell lines. The MRP-1 immunoreactivity of cell 
lines predicted carboplatin sensitivity and xCT predicted pemetrexed effect.  
 
Large individual variability was observed in the drug sensitivity of the primary cells. 
The cell isolates were affected by between one and ten drugs and actinomycin D and 
daunorubicin were the most potent drugs. When adjusting the drug efficiency for 
theoretical effect on benign cell isolates and for the varying proportion of tumor cells 
we observed better correlations with pemetrexed, cisplatin and survival time. 
Proportion of malignant cells, reactivity to RRM1 and general drug sensitivity 
correlated to each other and to survival of the patients. 
 
The drug sensitivity in malignant mesotheliomas is highly variable. These results 
indicate that in vitro testing of drug sensitivity may provide a tool for personalized 
treatment options.  
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1 BACKGROUND 
1.1 BIOLOGY OF THE PLEURAL CAVITY 
1.1.1 General 
The pleural cavity is the sealed space between the two layers of the pleura, the visceral 
and parietal pleurae, which surround the lung. The two layers arise from one 
continuous serous membrane connected at the hilum of the lung. The pleura consist of a 
flat and thin monolayer of cobblestone like mesothelial cells on a basement membrane, 
with a connective tissue underneath
1
. These cells, covering the pleural surface, 
originate from the mesoderm, grow in a pattern resembling epithelial cells and the 
tissue is therefore called the mesothelium. The pleura covers both lungs and 
anatomically they are separated by the mediastinum with no connection between the 
two pleural cavities
2
.  
 
The visceral pleura is the inner layer covering the lung, while the parietal pleura is the 
outer layer, covering the inside of thoracic wall, mediastinum and diaphragm. The 
visceral pleura is poorly innervated and shares blood supply with the lung through the 
bronchial arteries. Blood and lymph vessels are connected to the visceral pleurae 
through the connective tissue, which also protects the lung by restricting the inflation 
volume and contributes to elastic recoil of the lung after inhalation. The intercostal 
arteries supply the parietal pleura with blood and the tissue is innervated by intercostal 
and phrenic nerves
3
. In the parietal pleura, the mesothelial stomata are found. These are 
channels between mesothelial cells connecting the pleural cavity to the lymphatic 
system
4
. 
 
The mesothelial cells have microvilli on the apical side and cells are attached to each 
other by tight junctions and reside on the basement membrane underneath. In the 
inactive form, mesothelial cells are flat with a polygonal shape and few organelles. 
When activated, mesothelial cells round up, their nuclei enlarge, show a prominent 
nucleolus, increased numbers of pinocytic vesicles and an increased number of 
organelles involved in protein synthesis
5
.  
 
1.1.2 Function 
The pleural cavity normally contains an evenly distributed thin layer of pleural fluid 
that functions as a protective barrier and as lubricate to minimize friction between the 
two pleural layers while breathing. This lubricant contains glycosaminoglycans such as 
hyaluronan, which is synthesized and secreted by mesothelial cells
6
. The volume of this 
fluid is regulated by the mesothelial cells together with the movement of proteins and 
fluids across the serous membrane. Small molecules and water can pass between 
mesothelial cells by passive diffusion while larger molecules and proteins are actively 
transported by pinocytic and cytoplasmic vesicles
7,8
. 
 
By expressing intercellular adhesion molecule-1 and by activating T-cells through 
antigen presentation, the mesothelial cells initiate some of the immune response in the 
serous membranes
9
. The cells further participate in the response to foreign agents, such 
as asbestos, by secreting cytokines, chemokines, growth factors and extracellular 
matrix molecules
5,10
. When this occurs, a massive leukocyte migration into the serosal 
space is initiated. Some of the mesothelial cells are stimulated and become reactive 
with more microvilli expression and an altered morphology
11
. Mesothelial cells can 
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participate in coagulation by secreting tissue factors and have a fibrinolytic activity by 
secreting tissue plasminogen activator
12
.  
 
The mesothelial layer is delicate and quite sensitive to tissue damage. When disrupted, 
cells secrete a variety of growth factors and extracellular matrix molecules. This 
initiates mesothelial cell division and migration at the wound edge. Attachment and 
incorporation of free-floating mesothelial cells from the pleural fluid, stimulated by 
macrophages, is also a central part of healing the injury
5,13,14
. 
 
1.1.3 Pleural fluid 
Pleural fluid is the small amount of fluid produced by the normal pleurae. When this 
fluid is accumulated due to a pathological process it is called a pleural effusion. Under 
normal conditions the pleural fluid is continuously produced, secreted into the pleural 
cavity and reabsorbed by caveolar endocytosis in mesothelial cells. The reabsorption is 
adapted to an increased secretion and can be greatly increased before fluid accumulates 
in the pleural space. Therefore, a substantial increase in pleural fluid production or an 
inhibition of reabsorption has to occur to yield an increased amount of pleural fluid. 
Events causing this are lymphatic obstructions, increased microvascular permeability, 
decreased colloid osmotic or intrapleural pressure, and increased capillary venous 
pressure
15
. 
 
1.1.3.1 Pathological features 
Pleural effusion hampers the expansion of the lung, and thereby the ability of the 
patient to breathe properly. It is therefore drained by pleurocentesis in order to ease 
respiration. This fluid is also studied to establish the etiology of the effusion. The first 
step is to determine if the effusion is transudative or exudative. This can be established 
by measuring the levels of proteins and lactate dehydrogenase. Exudates have a higher 
ratio of the two measurements in the pleural fluid compared to the serum
16
. 
Transudative pleural effusions are usually a consequence of pressure changes in the 
cardiovascular system caused by heart failure, cirrhosis and nephrotic syndrome, 
diseases not originating in the pleura
17
. Exudative pleural effusions are usually caused 
by infections, malignancies or granulomatous disease in the pleura or lung. An 
infectious cause of the effusion can be established by culturing for bacteria and fungi, 
testing for tuberculosis and measuring glucose levels
18
.  
 
The possible presence of an alien cell population in the effusion is established by a 
cytopathological evaluation. The cellular morphology is observed in smears, stained 
according to Papanicolaou and/or May-Grünewald-Giemsa. This provides useful 
information for the choice of further analyses. By immunocytochemistry it is often 
possible to diagnose malignancy by the demonstration of reactivity to epithelial 
markers such as epitopes related to epithelial cell adhesion molecules, thyroid 
transcription factor-1 (TTF-1), carcinoembryonic antigen (CEA) and epithelial 
membrane antigen (EMA) in combination with mesothelial markers such as calretinin 
and desmin
19
. The issue of distinguishing malignant cells from reactive mesothelial 
cells can preferably be addressed by double staining for EpCam and calretinin to 
distinguish an alien epithelial cell population from reactive mesothelium, and desmin 
together with EMA to indicate malignancy of mesothelial cells by loss of desmin 
reactivity and cell membrane accentuation of the EMA stain. To establish a malignant 
diagnosis, ultrastructure analysis is performed with electron microscopy and cell ploidy 
can be studied with fluorescence in situ hybridization (FISH)
20
. Further information, 
particularly when suspecting malignant mesothelioma, can also be obtained from 
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measuring levels of the soluble biomarkers, hyaluronan and mesothelin by enzyme 
linked immunosorbent assay (ELISA)
21
.  
 
Using these adjuvant analyses, clinical cytology can often provide information 
concerning the origin of the tumor and in some cases predict possible therapy effects. 
In some cases epidermal growth factor receptor mutation or deletion and echinoderm 
microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion protein are 
observed, tumor driving mechanisms for which targeted therapies are available
22,23
. In 
patients with malignant pleural effusion a pleurodesis is often performed to prevent 
recurrence of a pleural exudate
24
. 
 
1.2 MALIGNANT MESOTHELIOMA 
1.2.1 General 
Malignant mesothelioma is a rare and fatal tumor originating from the mesothelial 
tissue. The site of the neoplasm is principally in the pleura, but it also occurs in the 
peritoneum, pericardium or tunica vaginalis testis. Exposure to asbestos is a risk factor 
independent of tumor localization
25-28
. Due to the association with asbestos exposure 
this tumor is often the result of industrial practices. The development of a 
mesothelioma is a lengthy process, the tumor appearing 25-60 years after asbestos 
exposure
29,30
. Therefore the typical mesothelioma patient is a male over 60 years
31,32
.  
 
1.2.2 Incidence  
The incidence of malignant mesothelioma is still increasing due to the long latency 
time and mainly affects industrialized countries where asbestos exposure has previously 
occurred. Australia has the highest reported incidence of malignant mesothelioma with 
annual rates of 40 cases per million
33
. This is because of the extensive and long term 
mining and import of asbestos and asbestos containing goods. Today the awareness of 
the neoplasm is widespread in Australia, with advanced diagnostic practice and well 
developed national surveillance systems
34
. In the United States the incidence is 15 
cases per million with statistically significant increases of incidence in areas with a 
history of shipbuilding
33,35
. 
 
In Europe the average incidence is 18 cases per million, with the highest incidence in 
Great Britain and the Netherlands, with 33 and 30 cases per million, respectively
33
. 
Europe has long been a big producer and consumer of asbestos. The use started to 
decrease in the 1970s through different prohibitions whereas in some European 
countries the complete ban did not occur until recently. The incidence is especially high 
in areas with large shipyards
36,37
. In Sweden the use of asbestos was banned in the mid-
1970s but still around 100 cases of malignant mesothelioma are diagnosed every year 
and the incidence is related to previous use of asbestos in shipyards and construction 
industry. Apart from shipyard workers many persons affected by the neoplasm have 
been plumbers or people working with insulation, but is also common among concrete 
workers, painters and electricians. Nowadays, asbestos exposure in Sweden mainly 
occurs through different materials remaining in constructions from 1970 or older
38
.  
 
The incidence of mesothelioma in most affected countries is expected to peak during 
the next decade and might already have been reached in some countries
35,39-41
. Because 
of the long latency time and differences in when asbestos use was prohibited, the 
incidence between these countries varies. However, the use of asbestos is still not 
banned in several countries and is increasing in parts of Eastern Europe and Asia. 
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Russia and China are the main consumers and producers and the global incidence is 
expected to increase for many decades to come
42,43
.  
 
1.2.3 Localization of malignant mesothelioma 
1.2.3.1 Malignant pleural mesothelioma 
Malignant pleural mesothelioma is a serosal tumor arising from the mesothelium of the 
pleural cavity, with a predisposal for the parietal pleura
30,44
. As mentioned above, most 
cases are caused by exposure to asbestos, reported for the first time in 1960
45
. This 
causality has been shown through; heterogeneous accumulation of asbestos fibers in the 
parietal pleura, correlation of intensity and frequency of exposure to the risk of 
developing the disease and the consumption levels of the mineral as a predictor of 
malignant pleural mesothelioma rate in different populations
46-48
. 
 
There are two main classes of asbestos, the serpentines and the amphiboles. Chrysotile 
is the most common serpentine accounting for 95% of all asbestos that has been mined 
in the world and the only type still being used. The carcinogenicity of chrysotile is 
lower than other types of asbestos but its extensive use will make it responsible for a 
large proportion of the malignant mesothelioma cases during the coming decades
49
. 
The amphiboles mainly consist of crocidolite, amosite, tremolite, anthophyllite and 
actinolite. The first three are more carcinogenic in pleural mesothelioma than the 
chrysotile fibers
49
. The properties of asbestos that makes it useful are its tensile 
strength, resistance to different external influences and ability to insulate. This 
affordable mineral has therefore been used in different types of electrical and building 
installations
50
. 
 
The mesotheliomas caused by asbestos can be divided into two different groups, 
environmental and occupational. The environmental mesotheliomas are caused by 
natural exposure to asbestos in areas where the mineral is present. These 
mesotheliomas are mainly caused by amphiboles in areas where houses have been 
painted white with products containing the mineral or in areas near to an asbestos mine 
or factory
50,51
. In the Cappadocia region of Turkey there is an asbestos-like mineral 
called erionite present in rocks. These rocks have been used to build houses in several 
villages and the mineral itself creates a white powder that has been used to paint walls. 
The tumorigenesis of erionite has been shown to be strong, responsible for an 
extremely high incidence of mesotheliomas in these Turkish villages
52
. 
 
Occupational mesotheliomas are caused by exposure directly in asbestos mines but also 
through exposure when handling asbestos containing material. Professions like 
shipbuilders, construction workers, electricians and plumbers are heavily affected by 
malignant pleural mesothelioma. Nowadays, the amount of people occupationally 
exposed to asbestos is larger than the amount environmentally exposed
53,54
.  
 
Mining of different minerals is important in Sweden but asbestos has never been 
mined. However, when other minerals are extracted, some asbestos exposure occurs, 
which previously has caused a few cases of malignant pleural mesothelioma. The 
remaining mines are today carefully controlled to avoid asbestos exposure. Asbestos 
was instead imported to Sweden, starting in the 1930s and lasting until the prohibition 
in the mid-1970s. Today there are strict rules for handling the remaining material 
containing asbestos
55
. 
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1.2.3.2 Other malignant mesotheliomas 
Malignant peritoneal mesothelioma accounts for a smaller proportion of the 
mesothelioma cases. In Sweden some 10% are peritoneal, while other studies have 
reported figures around 25%
32
. The median survival time is less than one year, first 
symptoms are abdominal distress and the tumor is often diagnosed at a late stage
56
. 
When possible, radical cytoreductive surgery followed by intraperitoneal hyperthermic 
chemoperfusion with a combination of cisplatin, doxorubicin, paclitaxel, 5-ﬂourouracil 
or mitomycin C is a therapeutic alternative
57
. When surgery is not possible, patients 
receive palliative treatment by systemic or local chemotherapy with cisplatin in 
combination with pemetrexed
58
. 
 
Although quite rare, malignant mesotheliomas can also develop in the pericardium and 
in the tunica vaginalis testis. The mean survival time in pericardial mesothelioma is less 
than eight months and surgery is the main treatment modality even though good 
response to pemetrexed and carboplatin has been reported
59
. Testicular mesothelioma 
can be treated with radical orchiectomy and chemotherapy if metastases are present, 
with a mean survival time of up to three years
60-63
. In this thesis we focus on studying 
malignant pleural mesothelioma. 
 
1.2.4 Pathogenesis 
The exact mechanism of asbestos tumorigenesis in malignant mesothelioma is not 
completely understood. Asbestos fibers are thin and sharp and can perforate cellular 
membranes without killing the cells. This can disturb cell division and cause 
aneuploidy and structural abnormalities in the chromosomes of daughter cells
64
. The 
asbestos fibers also generate reactive oxygen species, causing oxidative stress and 
cellular damage, triggering DNA alterations. This occurs through catalysis of radical 
reactions by iron in the asbestos fibers and the release of reactive oxygen species by 
phagocytizing macrophages and neutrophils, activated by asbestos
65-67
. Altogether, 
asbestos causes a permanent state of cellular damage, chronic inflammation and 
regeneration in the lung and pleura, seen as a pleuritis in some patients, and these are 
thought to be the main causes of malignant mesothelioma development
68
.  
 
Several common cytogenetic changes in malignant pleural mesothelioma are 
consequences of these events. These include deletions of the short arms on 
chromosome 1, 3 and 9 and the long arms on chromosome 6 and 22
54,69-71
. Several 
important loci are located in these chromosome arms such as; cyclin-dependent kinase 
inhibitor 2A (CDKN2A, 9p21), neurofibromin 2 (22q12) and breast cancer 1, early 
onset-associated protein 1 (BAP1, 3p21). These are all tumor suppressor genes 
frequently inactivated in malignant mesothelioma cells
72,73
.  
 
The CDKN2A locus encodes for the p16
INK4A
 and p14
ARF
 protein. p16
INK4A
 inhibits 
cyclin D1 from binding cyclin D-dependent kinases 4 and 6, a complex that 
phosphorylates and inactivates the retinoblastoma protein, which is a central step for 
initiating entry into S-phase in the cell cycle
74
. p53 is not mutated in malignant pleural 
mesothelioma but is inactivated by mouse double minute 2 homolog (Mdm2)
75-77
. In 
normal cells the Mdm2 inactivation is regulated by p14
ARF
 and when this protein is 
mutated, Mdm2 is active and binds p53
78,79
. This blocks important function of p53 in 
the control of DNA repair, cell cycle and apoptosis
80
. The CDKN2A locus is reported 
to be disrupted in a majority of the malignant pleural mesothelioma cases
72,81
. 
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Moesin-ezrin-radixin-like protein (merlin) is encoded by the neurofibromin 2 locus. 
Merlin is a membrane scaffolding protein in the cytoskeleton with the function to 
process extracellular signals and transmit them inside the cell. These signals mainly 
concern contact-dependence of cells and when cell-cell contact is lost, the protein 
function as a tumor suppressor by signaling for growth inhibition, decreased 
proliferation and increased apoptosis
82
. Around 50% of malignant pleural 
mesotheliomas have a disrupted neurofibromin 2 gene but it remains unclear if the 
remaining patients express functional merlin
70,83,84
. 
 
The BAP1 gene produces a deubiquitinating enzyme that removes ubiquitin from 
proteins and other molecules to prevent degradation. By doing this, the protein affects 
several processes in the cell such as DNA repair, cell cycle progression, differentiation 
and apoptosis. All these functions are central in cancer development and the BAP1 
locus is mutated in approximately 30–60% of mesotheliomas73,85. 
 
Besides these genes and proteins, several others have been studied to understand the 
apoptosis resistance in malignant mesothelioma cells
86
. No dominant DNA alterations 
have been found but increased levels of the inhibitor of apoptosis protein family, with 
the X-linked inhibitor of apoptosis protein and survivin have been reported
87,88
. 
Mitochondria are involved in the apoptosis resistance through the Bcl-2 family but the 
role of these proteins in mesothelioma is unknown
86,89
. The expression of c-fos and c-
jun, together forming activator protein 1, is induced by asbestos and might have a role 
in mesothelioma but the pathogenesis of malignant pleural mesothelioma needs to be 
further elucidated
90
.  
 
1.2.5 Diagnosis 
The diagnosis of malignant pleural mesothelioma is often complicated, involving 
several different examinations. The first symptoms displayed by patients are usually 
chest pains, shortness of breath, tiredness and poor physical functioning with 
difficulties to perform even a short walk, causing a reduced quality of life
91
. These 
symptoms arise as a result of decreased ability of the patients to expand the lungs 
during inhalation and are mainly caused by a pleural effusion. To alleviate these 
symptoms and make a correct diagnosis, the fluid is withdrawn by pleurocentesis. 
 
1.2.5.1 Imaging 
Many malignant pleural mesotheliomas are initially detected by chest radiography as a 
pleural mass or diffuse pleural thickening and with a simultaneous pleural effusion. 
When these changes are seen, the tumor is in most cases already advanced; earlier 
stages are not possible to demonstrate with chest radiography. An x-ray computed 
tomography gives additional information concerning pleural plaques associated with 
asbestos exposure, general pleural thickening and occurrence of a pleural effusion. 
Particularly in combination with positron emission tomography, which after uptake of 
fluorodeoxyglucose demonstrates metabolically active cells, many malignant pleural 
diseases can be detected. This examination can provide additional information 
concerning the spread of the neoplasm as well as evaluate treatment response in 
patients with malignant pleural mesothelioma
92-94
.  
 
Together, these visualizing methods might indicate a malignant disease but for the 
origin to be established and to give a conclusive diagnosis, cytopathology or 
histopathology is needed. The majority of the tumors in the pleura have metastasized 
from other locations rather than being a malignant mesothelioma. The pleural fluid is 
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often the first material available for such morphological evaluation, aiming at 
establishing of precise diagnosis.  
 
1.2.5.2 Cytology 
The pleural effusions are separated into transudates and exudates as described in 
section 1.1.3. The transudates are caused by non-malignant diseases not originating in 
the pleura, while a malignancy is one cause of an exudate. Exudative pleural effusions 
are cytologically evaluated after staining of smears according to Papanicolaou and/or 
May-Grünewald-Giemsa. The cytomorphological features indicating malignant 
mesothelioma cells are high cellularity, papillary cell aggregates, cell membrane 
protrusions, acidophilic cytoplasmic vacuoles, background extracellular material and 
nucleolar prominence
95
. 
 
Immunocytochemical staining is performed to show the presence of several epitopes in 
malignant mesothelioma cells. Immunological markers of mesothelial lineage include 
calretinin, HBME-1, mesothelin, Wilms tumor-1and D2-40. Strong positive membrane 
EMA reactivity is seen in a majority of mesotheliomas
95,96
. Combining this reactivity 
with negative staining for epithelial markers CEA and EpCam is fully predictive for 
mesotheliomas, however with a sensitivity of only around 50 %
96
. One marker 
distinguishing between malignant and reactive mesothelial cells is desmin, which is 
often lost early during oncogenesis. The use of double staining techniques helps in the 
evaluation of cases with atypical or non-specific staining, which is often weaker. Thus, 
double staining for EpCam and calretinin clarifies if a cell population is metastatic or 
mesothelial, while in most cases staining including EMA and desmin will reveal if the 
mesothelial cell is malignant or reactive
96
. 
 
1.2.5.3 Fluorescence in situ hybridization 
To strengthen a malignant diagnosis, the chromosomal ploidy of the cells can be 
studied by FISH. Using a commercial regent kit (Urovysion®) this FISH is performed 
using four directly labeled DNA-probes that hybridize to the centromere region on 
chromosomes 3, 7 and 17 and to the CDKN2A gene. A cell is considered to be 
malignant if the reaction to centromeric probes is increased in number in at least two of 
the chromosomes or if the CDKN2A gene is missing
20
. 
 
1.2.5.4 Biomarkers 
A malignant mesothelioma diagnosis is supported by measuring levels of soluble 
biomarkers. High levels of hyaluronan (above 75 µg uronic acid/mL) is a strong 
indicator for malignant pleural mesothelioma and combined with the N-
ERC/mesothelin the diagnostic accuracy is further increased
21,96-98
. 
 
1.2.5.5 Electron microscopy  
Electron microscopy can be used to differentiate between mesotheliomas and other 
malignant diseases that have metastasized to the pleural cavity. By looking at the 
ultrastructure of the malignant cells, mesothelial cells have several features that differ 
from other neoplasms such as; thin and very long apical microvilli without glycocalyx, 
large desmosomes, prominent anchoring junctions, basal lamina and perinuclear 
distribution of tonofilaments
96,99,100
. 
 
In summary, effusion cytology in combination with FISH, biomarkers and electron 
microscopy is adequate in diagnosing malignant pleural mesothelioma
95,96
. This is, 
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however, still debated. The latest guidelines for diagnosing malignant mesothelioma 
state that the diagnoses should be based on histological samples and staining, although 
complementary guidelines are currently being formulated
99
. 
 
1.2.6 Phenotypes 
There are two different phenotypes of malignant mesothelioma cells, one with 
epithelial cobblestone-shaped cells and one with sarcomatoid fibroblast-like cells. 
Several studies have demonstrated that there is a difference in the gene-expression 
between the two phenotypes
101-103
. This difference results in a phenotype-dependent 
sensitivity to experimental and conventional drugs seen in our previous studies
104,105
. 
Similar differences are seen in patients where these two phenotypes give three different 
histological patterns: one dominated by the epithelioid cells, one dominated by 
sarcomatoid cells and one biphasic type showing a mixture of the other two 
phenotypes
32
. A presence of non-epithelial cells in the tumor is associated with shorter 
survival time and increased therapy resistance
106-108
.  
 
Epithelial-mesenchymal transition (EMT) is the process when epithelial cells transform 
into mesenchymal cells. During this transition, E-cadherin is downregulated and N-
cadherin is upregulated. Increased levels of stress ﬁbers and focal adhesions can also 
been seen while cell-cell junctions are decreased and disrupted. Morphologically this 
transformation also causes actin cytoskeleton reorganization and increased migratory 
characteristics
109
. EMT is essential in developmental processes including mesoderm 
formation and occurs in wound healing. In the malignant tumor such conversion is seen 
as the tumor cells infiltrate and disseminates and when forming the metastatic lesions 
the cells regain their epitheliolid characteristics by mesenchymal-epithelial transition 
(MET). In malignant mesothelioma cells, with their dual phenotype, EMT and MET 
seem to be frequent, epithelioid and sarcomatoid cells being transformed into each 
other. These conversion reactions seem to be controlled by signals from 
microenvironment influencing the malignant potential of the tumor
110,111
. 
 
1.2.7 Treatment 
The malignant pleural mesothelioma is in most cases comparatively resistant to 
therapy, and attempts to cure the disease are often associated with significant co-
morbidity. The main treatment option for most cases is chemotherapy, described in 
further details in section 1.5. In early stages of the disease, surgery might be an option 
for patients. The most radical attempt is extrapleural pneumonectomy (EPP) where the 
entire affected pleura is removed together with the lung, sometimes also including 
partial or complete removal of diaphragm. An alternative is the less radical 
pleurectomy or decortication (P/D), with local resection of tumor tissue in pleura, lung 
and chest wall. 
 
An EPP decreases the quality of life, has a high perioperative mortality rate and the 
procedure does not seem to be beneficial compared to other treatment options
112,113
. 
Video-assisted thoracoscopic surgery pleurectomy or decortication has a better 
outcome, with lower patient mortality rate, a better quality of life and improved 
survival time for patients
114-116
. Patients with a tumor dominated by epithelioid cells 
and without weight loss benefits most from the procedure with a longer survival 
time
117
.  
 
Radiotherapy is mainly used to decrease pain from local tumor masses, thereby 
increasing patient quality of life. Treating patients with radiotherapy seem to improve 
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survival time but has not been compared to other treatments in randomized 
studies
118,119
. Adjuvant radiotherapy to surgery may reduce local recurrence and 
prolong survival
120
. The combination of surgery, chemotherapy and extensive 
radiotherapy in trimodality protocols has shown to improve local tumor control
121-125
. 
This procedure is, however, associated with substantial co-morbidity, preventing more 
general use.  
 
1.2.8 Prognosis 
Generally the prognosis for patients with malignant pleural mesothelioma is poor with a 
mean survival time from diagnosis of 12 months
33,126
. Patients with neoplasm 
dominated by epithelial cells have a better prognosis and a few are long time survivors, 
surviving several years after their diagnosis. Treatment with standard chemotherapy 
increases the average survival by three months and longer survival is seen in patients 
responding to chemotherapy
127
. Factors associated with a poor prognosis and shorter 
survival time are male sex, higher age, dyspnea, tumor stage, involvement of the 
visceral pleura, low hemoglobin level, high lactose dehydrogenase, a high thrombocyte 
and white blood cell count, pain and loss of appetite and weight
108,128-130
. The obtained 
survival times depend on the limited rate of tumor response, which motivates the search 
for tests that may optimize the choice of drugs and drug combinations.  
 
1.3 CHEMOTHERAPY 
1.3.1 General 
The first clinical trial using chemotherapy was carried out in 1943 when patients with 
different hematological malignancies demonstrated remarkable improvement after 
intravenous injections of mustine hydrochloride (nitrogen mustard)
131,132
. The 
malignancy soon recurred in these patients and a few years later, children with acute 
leukemia treated with aminopterin achieved longer temporary remission
133
. The first 
curative effect of chemotherapy was seen on gestational choriocarcinoma patients 
treated with methotrexate and 6-mercaptopurine
134
.  
 
Although chemotherapy was effective in hematological cancers, results in solid tumors 
were disappointing. This was changed when fluorouracil was discovered and when 
chemotherapy was used adjuvant to surgery
135-137
. Chemotherapy is also used 
neoadjuvant to radiotherapy or surgery, mainly to reduce tumor burden and decrease 
risk of metastases
138,139
.  
 
Most drugs target dividing cells, a characteristic for many malignant cells. However, 
normal dividing cells are also affected, causing cell death in bone marrow, digestive 
tract and hair follicles. This is the reason for the most common side effects; 
gastrointestinal distress, alopecia, myelosuppression, leukopenia, anemia and 
thrombocytopenia, increasing the susceptibility for infections
140
.  
 
1.3.2 Classification of anticancer drugs 
Chemotherapeutical drugs are divided into different groups, according to their 
mechanisms of action, as follows. Table 1 summarizes the chemotherapeutical agents 
included in this thesis.  
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Table 1. The 31 chemotherapeutical drugs included in this thesis, divided according to their 
mechanism of action. 
 
1.3.2.1 Alkylating agents  
This group of drugs covalently binds macromolecules, including proteins, RNA and 
DNA. There is no speciﬁcity with these chemotherapeutical agents but the main 
cytotoxic effect is random binding and forming adducts in DNA
141-143
. A majority of 
the agents bind alkyl groups to DNA but this group of drugs also includes other 
compounds, binding in a similar fashion. This binding hampers DNA synthesis and 
stops cell cycle progression, causing apoptosis.  
 
Nitrogen mustards are the oldest group of alkylating agents and mustine hydrochloride 
was the first nitrogen mustard used, as described above. The nitrogen mustard was 
developed by adding other chemical moieties and alkylators such as melphalan and 
chlorambucil were developed
144-148
. 
Alkylating Agents Nitrogen mustard Chlorambucil 
 Platinum Cisplatin 
  Carboplatin 
  Oxaliplatin 
 Aziridine Mitomycin C 
 Tetrazine Dacarbazine 
Antimetabolites Pyrimidine analogues Fluorouracil 
  Cytarabine 
  Gemcitabine 
 Purine analogues Mercaptopurine 
  Fludarabine 
  Cladribine 
 Antifolates Methotrexate 
  Pemetrexed 
 Other Hydroxyurea 
Antimicrotubule agents Taxanes Paclitaxel 
  Docetaxel 
 Vinca alkaloids Vinblastine 
  Vincristine 
  Vinorelbine 
Topoisomerase inhibitors  Type I Topotecan 
  Irinotecan 
 Type II Etoposide 
  Amsacrine 
Proteasome inhibitor   Bortezomib 
Multifunctional drugs Anthracyclines Daunorubicin 
  Doxorubicin 
  Epirubicin 
 Other Actinomycin D 
  Bleomycin 
Experimental drug  Selenite 
   11 
 
Drugs containing a platinum atom are widely used because of their potency. The 
platinum atom binds different molecules in the cell and creates adducts when binding to 
DNA, causing inter- and intrastrand cross linking and hence apoptosis in a similar 
fashion to alkyl groups
149,150
. Cisplatin (figure 1A) is the most common platinum 
analogue, inactive in its original form but positively charged and reactive after a 
stepwise aquation inside cells
151
. The compound is used in several different 
malignancies and cures nearly 100% of testicular cancer. Together with pemetrexed it 
is the standard treatment for malignant pleural mesothelioma
152-155
. Carboplatin (figure 
1B) is the second generation of platinum compounds and is an analogue to cisplatin 
with a bidentate cyclobutanedicarboxylate ligand in its molecular structure, adding 
stability and causing a slower aquation
150
. The compound was discovered in a mass 
screening of compounds effective on in vitro cultured tumor cell lines
156
. The effects of 
carboplatin were studied in six mesothelioma cell lines in paper III. Carboplatin has 
been shown to be less toxic than cisplatin and is used in treatment of patients with non-
small cell lung cancer and ovarian cancer
157-159
. Resistance to cisplatin and carboplatin 
is a major problem. Therefore, oxaliplatin was developed as the third generation and 
was shown to be effective in cisplatin resistant cell lines
160-162
. Oxaliplatin (figure 1C) 
seems to act in the same way as cisplatin and carboplatin and is used in treatment of 
patients with ovarian cancer
163
.  
 
 
 
 
 
 
 
 
 
Figure 1. The chemical structure of the three platinum drugs included in this thesis. A. 
Cisplatin. B. Carboplatin. C. Oxaliplatin. Pictures adapted from Wikimedia Commons. 
 
Mitomycin C, isolated from Streptomyces caespitosus, is a member of the aziridines 
(all contain an aziridine ring) and needs to be reduced before binding and creating 
adducts in DNA
164,165
. Today, mitomycin C is used in several different drug 
combinations in lung and colorectal cancer
166,167
. Dacarbazine is a tetrazine, which 
means that it consists of an aromatic ring with four nitrogen atoms. The compound is a 
purine analogue but it seems like it exerts its toxic effect by binding DNA as an 
alkylator
168,169
. Dacarbazine is the main treatment of malignant metastatic melanoma
170
. 
 
1.3.2.2 Antimetabolites 
This group of chemotherapeutical agents is structurally similar to the basic substances 
in DNA and RNA and therefore interferes with their synthesis. DNA and RNA are 
assembled from nucleotides that consist of a nucleobase, a phosphate and a sugar 
group
171,172
.  
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Figure 2. The chemical structure of pyrimidine (A) and purine (B). Pictures adapted from 
Wikimedia Commons. 
 
The pyrimidine and purines analogues are two groups of antimetabolites that resemble 
the respective nucleobases or nucleosides (nucleobases with a sugar group, figure 2). 
Their mechanism of action is similar; they are converted inside the cells to analogues of 
nucleobases or nucleosides. The compounds then inhibit enzymes central in DNA and 
RNA synthesis or becomes incorporated into DNA or RNA, inducing apoptosis
173
. 
 
Fluorouracil is the nucleobase uracil with the substitution of a hydrogen atom with a 
fluorine atom
135
. The compound blocks thymidylate synthetase, an enzyme important 
in the formation of building blocks for DNA
174
. Fluorouracil is similar in structure to, 
but does not perform the same chemistry as uracil; the drug inhibits RNA replication 
enzymes, thereby eliminating RNA synthesis. The metabolites also incorporate into 
DNA and RNA, and all together this inhibits DNA synthesis, causing apoptosis
175-177
. 
Fluorouracil was used to treat patients with both hematological and solid tumors but the 
severe side-effects limit the use of the drug today
178,179
. 
 
Cytarabine is the nucleobase cytosine with an additional hydroxyl and a sugar group. In 
the cell the drug acts as the nucleotide analogue deoxycytidine and incorporates into the 
DNA. This stops the DNA and RNA polymerases and DNA replication, causing 
apoptosis
180-182
. Cytarabine is used in patients with different types of leukemia
183
. The 
structure of gemcitabine is similar to cytarabine but with two fluorine atoms instead of 
the extra hydroxyl. The function is also similar but the converted gemcitabine in the 
cell also inhibits ribonucleotide reductase, an enzyme important for synthesis of 
nucleotides
184,185
. This causes apoptosis and the long half-life of gemcitabine 
metabolites improves the effect in several different solid tumors and hematological 
malignancies
186-191
. The cytotoxic effects of gemcitabine in six mesothelioma cell lines 
were studied in paper III. 
 
Mercaptopurine is an analogue to the purine nucleobase guanine without an amino 
group and the oxygen in guanine has been replaced by a sulfur atom. The agent inhibits 
proteins involved in de novo synthesis of purines and also incorporates into DNA 
causing DNA damage and altogether apoptosis
192,193
. Mercaptopurine was included in 
the first curative chemotherapy when treating gestational choriocarcinoma patients
134
. 
Today the drug is used in patients with acute leukemia
194
.  
 
Fludarabine is an adenine analogue with an extra fluorine atom. The compound is 
incorporated into DNA and inhibits the ribonucleotide reductase
195
. Fludarabine is used 
in different drug combinations and as single agent to treat chronic lymphocytic 
leukemia and follicular lymphoma
148,196
. Cladribine is structurally similar to 
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fludarabine but with a chlorine atom instead of the fluorine. The compound has the 
same mechanism of action as fludarabine and is the standard treatment for patients with 
hairy cell leukemia
195,197,198
. 
 
The antifolates constitute another group of antimetabolites that target enzymes essential 
for the synthesis of nucleotides. Methotrexate inhibits the enzyme dihydrofolate 
reductase, responsible for producing tetrahydrofolic acid, which is required for 
thymidylate production
199
. This causes cell cycle arrest and apoptosis. Methotrexate 
and the previously described agent mercaptopurine were used to cure choriocarcinoma 
patients in 1958
134
. Low dose methotrexate is still used to treat childhood acute 
lymphoblastic leukemia
200
. Pemetrexed is an antifolate that enters cells via the reduced 
folate carrier
201
. The agent mainly inhibits the enzyme thymidylate synthase, but also 
effects dihydrofolate reductase, aminoimidazole carboxamide ribonucleotide 
formyltransferase and glycinamide ribonucleotide formyltransferase, enzymes involved 
in purine and pyrimidine synthesis
202,203
. This causes S-phase arrest and apoptosis
204-207
. 
Pemetrexed in combination with a platinum drug is the standard treatment of patients 
with malignant pleural mesothelioma and is also used in non-small-cell lung 
cancer
155,208,209
. Drug resistance development in a patients treated with pemetrexed was 
studied in paper II. 
 
Hydroxyurea is an anticancer drug first synthesized in 1869 that inhibits the enzyme 
ribonucleotide reductase by eliminating radicals needed for the enzyme to produce 
nucleotides
210,211
. Hydroxyurea is used to treat patients with chronic myeloid leukemia 
and polycythemia vera
212
.  
 
1.3.2.3 Antimicrotubule agents  
A vital part of cell division is the assembly of tubulin molecules to form microtubules. 
Microtubules form the base of the mitotic spindles, which pull the chromosomes apart 
during cell division
213,214. The tubulin molecules are composed of two proteins; α-
tubulin and β-tubulin. The antimicrotubule agents are a group of plant-derived drugs 
that bind these molecules, preventing cell division and inducing apoptosis. There are 
two main groups of antimicrotubule agents, the taxanes and the vinca alkaloids, with 
the opposing mechanisms of action. Taxanes promote microtubule stability, preventing 
their disassembly, while the vinca alkaloids prevent the formation by disturbing the 
stability of the microtubules. 
 
The taxanes bind β-tubulin, which promotes polymerization of tubulin, stabilizing the 
microtubules and thereby inhibiting mitosis
215,216
. Paclitaxel is a taxane extracted from 
the yew tree, Taxus brevifolia or Taxus baccata. Pacitaxel has been used in treatment of 
patients with several different types of malignancies
217-220
. The docetaxel molecule 
differs from paclitaxel at two positions, making the compound more water-soluble. 
Docetaxel has a higher affinity for binding β-tubulin than paclitaxel, and is used to treat 
ovarian, breast, prostate and lung cancers
218,221-225
. 
 
Vinblastine is a vinca alkaloid that was discovered and extracted from the plant 
Catharanthus roseus (formerly known as Vinca rosea) and is today synthetically 
produced
226. Vinblastine binds β-tubulin at low concentrations inhibiting mitosis by 
stabilizing the microtubules and at higher concentrations by depolymerizing the 
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microtubules
227-229
. After the discovery of the drug, it was used in several different 
malignancies but it has since then been exchanged for more effective drugs in different 
treatment regimens
230
. Vincristine is another vinca alkaloid, also extracted from 
Catharanthus roseus and it is structurally very similar to vinblastine. The drug has a 
similar mechanism of action to vinblastine
231
. Vincristine is mainly used in 
combinations with other drugs to treat patients with different malignancies
232-234
. After 
the success of these two agents, vinorelbine was synthesized from the same plant
235
. 
Vinorelbine acts in the same way as the other vinca alkaloids and is used in treatment 
of breast cancer and non-small-cell lung cancer
236,237
. 
 
1.3.2.4 Topoisomerase inhibitors 
This group of drugs inhibits the actions of two groups of enzymes: the topoisomerase I 
and topoisomerase II. When processing DNA, during normal replication or translation, 
the double stranded DNA helix is unwound at the part that is being processed. The 
unprocessed parts are at the same time wound tighter and this creates a tension. The 
topoisomerases decreased this tension by producing temporary breaks in the DNA. The 
drug topotecan is metabolized in cells, inhibiting the function of topoisomerase I and 
causing permanent DNA strand breaks. The drug has been shown to be effective in 
treatment of ovarian and lung cancer
238,239
. Irinotecan is also metabolized in the cell, 
inhibiting topoisomerase I and is used in treatment of colon cancer
240
. The 
topoisomerase II is essential in cell division by removing links between chromosomes 
when segregated into the two daughter cells. Etoposide is a plant derivative that binds 
the topoisomerase II-DNA complex, inhibiting the enzyme and the drug is used in 
treatment of lung cancer and lymphomas
241-243
. Amsacrine increases the ability of 
topoisomerase II to break DNA, causing DNA damage and cell death
244
. The drug is 
used to treat tumors in urinary bladder and pharynx
245,246
. 
 
1.3.2.5 Proteasome inhibitors  
The proteasome is a protein complex in cells with the function of degrading proteins 
that have been damaged, are defective or not needed in the cell
247
. This protein complex 
is composed of one 20S subunit and two 19S subunits
248
. Many malignant cells have 
been shown to have a higher proteasome activity and expression than normal cells, 
making the proteasome a suitable target for chemotherapy
249,250
. Several different 
proteasome inhibitors have been proposed but so far bortezomib is the only one 
approved for treatment of cancer
251
. Bortezomib targets the 20S subunit of the 
proteasome and inhibits the function, causing accumulation of proteins in the cells and 
apoptosis
252,253
. The combination of bortezomib and doxorubicin is the standard 
treatment for recurrent multiple myeloma
254
. Mesothelioma cell lines were affected by 
bortezomib in paper III but in clinical trial the effect was disappointing
104,255,256
.  
 
1.3.2.6 Multifunctional drugs 
The anthracyclines constitute a group of drugs originating from the same chemical 
structure, a four-ringed organic quinone. This group is also known as antitumor 
antibiotics, due to their antibiotic effect. The mechanism of action of these drugs is 
multiple; the agents intercalate DNA, inhibit topoisomerase II, form DNA adducts, 
crosslink DNA, interfere with synthesis of macromolecular and generate reactive free 
radicals in cells damaging DNA and proteins
257
. The anthracycline daunorubicin was 
originally isolated from the bacteria Streptomyces peucetius and is used to treat patients 
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with leukemia
258-260
. Doxorubicin was isolated from the same bacteria and is 
structurally very similar to daunorubicin. Doxorubicin effects in six mesothelioma cell 
lines were evaluated in paper III and the drug is widely used in different drug 
combinations to treat patients with leukemias and solid tumors
261-263
. Epirubicin was 
developed from daunorubicin and doxorubicin. The cytotoxic actions of this drug are 
similar to the other anthracyclines but with less side-effects
264
. The compound is used 
to treat breast and gastric cancer
265,266
. Doxorubicin and daunorubicin are well known 
for their cardiotoxicity, which is the dose limiting factor in several treatments.  
 
Actinomycin D is a drug isolated from the bacteria Streptomyces parvulus
267
. The 
drug’s mechanism of action is by intercalating the DNA and interfering with the RNA 
polymerase, thereby preventing transcription and affecting the activity of 
topoisomerase I and II
268-270
. The compound is used to treat patients with some less 
common tumors such as gestational trophoblastic neoplasia, Wilms' tumor and 
rhabdomyosarcoma
271-273
. Bleomycin is a family of compounds isolated from the 
bacteria Streptomyces verticillus. Bleomycin A2 and B2 are the two forms of the 
compound that are effective and included in drug combinations when treating 
Hodgkin's and non-Hodgkin lymphoma patients
274-276
. Cell death by bleomycin mainly 
seems to be induced by bleomycin through inhibition of DNA synthesis and generation 
of free radicals, causing DNA strand breaks
277
. 
 
1.3.2.7 Selenite, a potent experimental drugs 
The apoptotic mechanisms and cytotoxic effects of the experimental drug selenite have 
been studied in paper I and III. Selenium is essential for cells, where low 
concentrations are vital for the cell survival, while high concentrations induce cell 
death
278
. Selenite is an oxidized form of selenium (SeO3
2-
) and the compound is easily 
reduced by cysteine to selenide (HSe
-
). The mechanism of cellular uptake of selenium 
is unknown but a reducing extra-cellular environment with cysteine increases the 
proportion of selenide and this increases the cellular uptake of the drug
279
.  
 
Inside the cell selenium reacts with thiols, forming reactive oxygen species and 
inducing oxidative stress, which causes apoptosis
105
. The mechanism of this is 
unknown and the essential part of this reactivity is demonstrated as decreased drug 
effect in cells with high expression of antioxidant proteins
280
. The selenite effect is 
hampered by the addition of antioxidant compounds, resulting in decreased formation 
of reactive oxygen species
105,281,282
. Malignant cells, including drug resistant ones, have 
been shown to be more sensitive to selenite treatment than benign cells
105,283-285
. 
Primary malignant cells collected from patients with leukemia are sensitive to the drug, 
and in patients selenite has been used in combination with other drugs, surgery and 
radiotherapy
286-289
. There are, however, still no large clinical trials evaluating the 
clinical usefulness of selenite. The effect of selenite on six mesothelioma cell lines, as a 
single agent or in different combinations with conventional drugs, was evaluated in 
paper III. 
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1.4 OTHER DRUGS 
1.4.1 Prednisone 
Prednisone is a glucocorticoid hormone metabolized in the liver to its active form 
prednisolone
290
. Glucocorticoids function by binding to their receptor in the cell, this 
complex enters the nucleus, interacts with DNA, changes the transcription and alters 
which proteins that are synthesized
291
. Prednisolone binds to the glucocorticoid 
receptors, changing protein expression, which reduces the side effects of drugs used in 
combination with prednisone and induces apoptosis
292,293
. Prednisone is used in 
treatment of lymphomas, multiple myeloma and prostate cancer in combination with 
other anticancer drugs
294-297
. 
 
1.4.2 L-asparaginase 
Some malignant cells are not able to synthesize asparagine and obtain this amino acid 
from an external source. L-asparaginase is an enzyme that catalyzes the hydrolysis of 
asparagine, thereby decreasing the amount of circulating asparagine in the body when 
administered to patients, causing inhibited protein synthesis in malignant cells and 
apoptosis
298
. L-asparaginase has limited effect when used as a single agent and 
therefore the enzyme is primarily used in combination with other anticancer drugs to 
treat patients with leukemia
299-301
.  
 
1.5 CHEMOTHERAPY FOR MALIGNANT PLEURAL MESOTHELIOMA 
1.5.1 Different combinations 
The standard chemotherapy used for patients with malignant pleural mesothelioma is 
the combination of cisplatin and pemetrexed
302
. In the original study, this treatment 
increased the survival time compared to patients treated with only cisplatin by 2.8 
months, yielding an average survival time of 12.1 months after diagnosis. The response 
rate was 41%. The increased side effects were suppressed by supplementation of folic 
acid and vitamin B12, which also increased the survival time.  
 
Several drug combinations have been evaluated but none of them have been superior to 
the standard treatment
303,304
. Exchanging cisplatin with carboplatin gives similar 
treatment outcome in patients
305,306
. Replacing pemetrexed with another antifolate, 
raltitrexed, showed lower response rates and shorter average survival time
307
. 
Combining cisplatin with gemcitabine instead of pemetrexed gave both higher and 
lower responses rates, but the average survival time was shorter
308,309
. Combining 
cisplatin with vinorelbine in a small phase II study presented interesting results with an 
average overall survival time of 16.8 months but these results need to be verified in a 
larger patient group
310
. Another small phase II study, treating malignant pleural 
mesothelioma patients with gemcitabine in combination with oxaliplatin, produced 
results comparable with the standard treatment
311
. Combining carboplatin, liposomized 
doxorubicin and gemcitabine resulted in a response rate of 32% and a survival time of 
13 months
312
. 
 
Together these clinical trials demonstrate the need for more effective treatment of 
malignant pleural mesothelioma patients. This is highlighted by results showing that 
patients responding to treatment have the longest survival time
127
. Recent studies have 
also indicated that treatment outcome of malignant pleural mesothelioma patients might 
be predicted by immunohistochemical demonstration of biomarkers
313,314
.  
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1.5.2 Predictive markers 
There are a great number of different potential markers for predicting the treatment 
effects of different chemotherapeutical agents. One goal is to find markers that predict 
the outcome of different treatment regimens before starting the treatment and thereby 
choose an individualized therapy for each patient from the start. This would be central 
in future treatment of malignant pleural mesothelioma since only 40% of patients 
respond to standard treatment, as described above. The approach of tailoring treatment 
according to expression of predictive markers has been used in non-small-cell lung 
cancer patients with promising results
315
. In paper III we have chosen to study seven 
markers that might be related to the sensitivity or resistance to doxorubicin, 
gemcitabine, carboplatin, pemetrexed, bortezomib or selenite. In paper IV we have 
studied two markers and their relation to general drug sensitivity and patient survival 
time. The potential predictive markers that were evaluated in this thesis are described 
below.  
 
P-glycoprotein (Pgp) is a membrane protein responsible for the transport of different 
substrates across cellular membranes. The protein is an effective drug efflux pump, 
decreasing cellular accumulation of several drugs
316
. Increasing levels of Pgp are often 
involved in development of drug resistance to several different anticancer drugs. This 
protein is often expressed in mesothelioma cells and  gp expression correlates to 
paclitaxel  and doxorubicin resistance in breast cancer317-319. Multidrug resistance-
associated protein 1 (MRP-1) is a membrane protein from the same transport protein 
family as Pgp and with a similar function. MRP-1 secretes cysteine, a central 
mechanism for cellular uptake of selenite, as described above
279
. The protein also has 
the ability to efflux a large amount of conventional drugs, is frequently expressed in 
cells from patients with malignant pleural mesothelioma and is significantly associated 
with poor outcome in patients with neuroblastoma treated with different conventional 
drugs
318-320
.  
 
Excision repair cross-complementing rodent repair deficiency, complementation group 
1 (ERCC1) is a protein in the nucleotide excision repair system, a system that repairs 
damaged DNA
321
. The protein is involved in resistance to platinum drugs and non-
small-cell lung cancer patients with low ERCC1 expression have been shown to 
respond better to cisplatin treatment
322-324
. In malignant pleural mesothelioma patients 
treated with pemetrexed and cisplatin or cisplatin and vinorelbine the overall survival is 
correlated to ERCC1 levels
314,325
. The ribonucleotide reductase large subunit M1 
(RRM1) is an enzyme and a subunit of the ribonucleotide reductase, a protein central 
for deoxyribonucleotide synthesis
321
. RRM1 is a predictive factor in several 
malignancies and is inactivated by gemcitabine
326,327
. Expressions of ERCC1 and 
RRM1 have been widely studied in patients with non-small-cell lung cancer and 
correlate to treatment effects of gemcitabine or carboplatin
328-332
.  
 
Thymidylate synthase (TS) is an important enzyme in folate synthesis, catalyzing a 
reaction central for the supply of building blocks for DNA. TS is the main target of 
pemetrexed and in non-small cell lung cancer patients treated with the drug the 
expression of TS predicts the clinical outcome
333,334
. In mesothelioma patients treated 
with pemetrexed the predictive value of TS has been widely studied and is still 
uncertain
335,336
. The Xc
-
 cystine transporter (xCT) is a cystine/glutamate antiport protein 
that transports extracellular cystine into the cells and glutamate out from the cell. The 
protein is vital for cellular regulation of cystine/cysteine levels and is expressed in 
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many different human cells
337
. Increased xCT expression induces resistance to 
gemcitabine and is central in selenite toxicity, as described above
279,338
. 20S proteasome 
(20S P) is a subunit of the proteasome, thus involved in protein degradation and the 
main target of bortezomib
247,253
. A higher proteasome expression and activity has been 
observed in some malignancies and in acute myeloid leukemia cells, high expression of 
20S P has been correlated to bortezomib sensitivity
250,339
. 
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2 AIMS 
There is a great need to improve and develop chemotherapy for malignant pleural 
mesothelioma. Less than 50% of patients respond to standard chemotherapy and 
treatment response yields an increased survival time
127,302
. This highlights the needed to 
identify which patients that fails in responding to treatment and find suitable 
chemotherapeutical treatment options for them.  
 
The overall aim of this thesis was to increase the understanding of drug sensitivity in 
malignant pleural mesothelioma and bring this knowledge from the bench closer to the 
bedside. These aims are achieved through dividing the thesis into four different studies 
with the following specific aims: 
 
Paper I:  To examine the phenotype dependent differences in apoptosis signaling 
of malignant pleural mesothelioma cell line after exposure to selenite, a 
potent experimental drug.  
 
Paper II:  To study the molecular mechanisms of pemetrexed resistance in 
malignant pleural mesothelioma.  
 
Paper III:  To evaluate the drug sensitivity of six phenotypically different 
malignant pleural mesothelioma cell lines treated with conventional and 
experimental cytostatic drugs as single agents or in combinations of 
two. To correlate the phenotype and drug sensitivity of cell lines to their 
immunocytological reactivity of potential predictive markers.  
 
Paper IV:  To characterize primary cells from patients with malignant 
mesothelioma, evaluate their ex vivo sensitivity to a broad panel of 
anticancer drugs, their cytological staining of RRM1 and ERRC1, and 
correlate to clinical outcome of these patients. 
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3 REMARKS ON METHODOLOGY 
3.1 CELL LINES 
Cell lines used in these studies included six malignant pleural mesothelioma cell lines 
and one T-cell lymphoma cell line. STAV-AB and STAV-FCS cell lines were 
previously established from a single pleural effusion and differentiated into different 
phenotypes by growing STAV-AB cells in 10% human AB-serum and STAV-FCS 
cells in a 10% mixture of bovine serum and fetal bovine serum. These two cell lines 
have previously been characterized by us as a model system to study phenotype 
dependent differences
340
. 
 
ZL-34 and M-14-K are grown in the same way as STAV-FCS cells and the 
length/width ratio and morphology of these three cell lines and STAV-AB cells have 
been previously studied
341
. DM-3 and JL-1 cell lines were grown in 20% fetal bovine 
serum and these two cell lines had the largest length/width ratios when all six cell lines 
were characterized in paper III. The phenotypes of the cell lines are consistent with 
previous finding that signals from the microenvironment effects the phenotype of the 
tumor
111
.  
 
We used the STAV-AB and STAV-FCS cell lines in paper I and III
342
. The ZL-34 and 
M-14-K cell lines were used in paper II and III. In paper III we also included the 
DM-3 and JL-1 cell lines
343-345
. In these projects, the STAV-FCS, ZL-34 and M-14-K 
cells were appointed with different phenotypes which was due to a more detailed 
characterization and strict definition in paper III. However, length/width ratios and 
growth characteristics of the cell lines were consistent in the different projects. The 
Jurkat T-cell lymphoma cell line was used as a control in paper I and III
346
. 
 
3.2 PRIMARY CELLS 
In paper IV we used eighteen malignant cell isolates from twelve patients diagnosed 
with malignant mesothelioma and four benign mesothelial cell isolates obtained from 
pleural effusions in patients with no malignant diagnosis. Twelve malignant and four 
benign cell isolates were seeded and grown to confluence before they were studied. 
Two of the effusions were also studied for several passages, two were repeated effusion 
from the same patient and in two of the effusions with papillary groups, these groups 
were separated and compared to simultaneously occurring disassociated cells at 
confluence. 
 
A pleural effusion is often the first diagnostic material received from a patient and this 
provides a more clinically relevant model to study. The pleural effusions that we 
receive and culture consist of the exudates with a high cellular content. The tumor cells 
in these fluids are mainly epithelioid, since sarcomatoid cells are usually not exfoliated. 
Furthermore, the microenvironment in the pleural cavity may trigger a differentiation of 
exfoliated tumor cells towards an epithelioid morphology.  
 
Culturing cells in vitro causes a certain amount of selection and we try to limit this by 
minimizing the culturing time. The cell isolates always contain a mixture of malignant 
mesothelioma cells, reactive mesothelial cells and inflammatory cells in unknown 
proportions. Attempts to evaluate the proportions of these different cell types were 
done by immunocytochemical demonstration of desmin, EMA and leukocyte common 
antigen. These stainings were examined by two cytopathologists, establishing the 
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proportion of malignant cells in all isolates except two cases, which were further 
evaluated with ploidy analysis.  
 
3.3 IMMUNOCYTOCHEMICAL CHARACTERIZATION 
The pretreatment of cell lines in paper III was optimized with control cells known to 
express the target protein. We used 5 minutes citrate buffer pH 6.0 as pretreatment for 
all targets except for Pgp, where an EDTA buffer pH 9.0 was used. The specificity of 
the primary antibody was demonstrated by using relevant isotype controls.  
 
The staining of primary cells in paper IV was optimized in the same way as for the cell 
lines. This resulted in the use of EDTA buffer pH 9.0 for 20 minutes to get a sufficient 
exposure of the epitope and thus good binding of the primary antibody. The staining 
pattern of different markers in the cell lines was evenly distributed within the cell 
population. In the more heterogeneous primary cell isolates, the reactivity was diverse 
but the staining intensity of only the malignant cells was evaluated by two experienced 
cytopathologists.  
 
The access to pleural effusions makes immunocytochemistry a suitable approach to 
evaluate levels of different predictive markers, compared to immunohistochemistry 
depending on a tissue sample from the tumor.  
 
3.4 VIABILITY OF CELLS 
In these projects we have used three different methods to measure the viability of cells 
after treatment with different anticancer drugs. The viability is obviously dependent on 
drug concentrations and in paper I and III we used concentrations corresponding to the 
IC30 values of STAV-AB and STAV-FCS cells. In paper IV we used four different 
dilutions of the drug concentrations, chosen to cover clinically relevant concentrations. 
Some of the concentrations were further adjusted to their clinical use, without affecting 
the outcome.  
 
Water Soluble Tetrazolium-1 (WST-1) is a tetrazolium dye cleaved by mitochondrial 
enzymes when added to cells. The product can be measured by spectrophotometry and 
is strictly correlated to the metabolic activity of the cell population and the amount of 
live cells. By comparing treated cells to control cells, it is possible to calculate the 
viability of cells after treatment. The dye is easily used and the method gives quick 
results. The disadvantage of the method mainly concerns the uncertainty of the readout. 
Since the dye measures metabolic activity, a general increase or decrease of this 
activity can be incorrectly interpreted as proliferation or cell death. These limitations 
were observed in paper III, when cells were recognized as unaffected using WST-1, 
while many of them were actually affected and arrested in s-phase, as shown with 
propidium iodide (PI) staining.  
 
In paper II and III we used PI to stain DNA in ethanol fixed cells and analyzed the 
staining by flow cytometry. Live cells in untreated controls were gated according to 
their forward/side scatter and when applying this gating on treated samples, live cells 
after treatment were gated and compared to the control cells. Gate settings are a 
limitation of this method and an advantage is that the cell cycle distribution of live cells 
is studied at the same time.  
 
When PI was used together with Annexin V in paper I, cells were unfixed. 
Consequently, PI only stained the DNA of cells in late apoptosis or necrosis with a 
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disrupted cell membrane. Annexin V has a high affinity for phosphatidylserine, a 
phospholipid flipped from the inside to the outside of the plasma membrane in the early 
stages of apoptosis
347
. Annexin V was bound to fluorescein isothiocyanate, a 
fluorophore, evaluated using a flow cytometer and when combining with PI staining, 
cells in early apoptosis can be identified. This method is useful when studying the 
apoptotic response in cell populations but not all cells express phosphatidylserine in the 
early stages of apoptosis
348
.  
 
In paper IV we used a recently established method measuring the ex vivo viability of 
cells after exposure to a broad panel of anticancer drugs
349-351
. The VitalDye measures 
cell viability and the number of living and dead cells is automatically counted and 
compared to control cells. This method is more effective than the WST-1 and PI 
method when it comes to measuring drug sensitivity but the method is sophisticated 
and complex to setup. 
 
These three methods give information concerning the state of cells at the measured time 
point but the effect of the drug before and after the readout is not studied. This is a 
limitation that might be overcome by doing measurements at different time points as 
was partially done in paper III.  
 
3.5 SIGNS OF APOPTOSIS 
Before apoptosis, several events occur in a cell and in this thesis we have studied a few 
of them. In paper I we inhibited different proteins in the apoptotic process and studied 
how this affected the apoptosis induced by selenite. This is a delicate issue and 
therefore inhibitor concentrations were carefully titrated, several negative controls were 
used and the outcome measured with different methods. The JC-1 probe was used to 
measure changes in mitochondrial membrane potential with positive controls and 
results were verified with the fluorescent 3,3-dihexyloxacarbocyanine iodide. Together 
this gives a picture of the apoptotic process in cells but unfortunately only at a specific 
time point and for the chosen apoptotic pathways. 
 
The PI staining intensity in cells, discussed in section 3.4, corresponds to the amount of 
DNA, enabling the evaluation of cell cycle distribution of live cells. By doing this and 
comparing to untreated control cells, an S-phase arrest in pemetrexed treated cells was 
seen in paper II and III. Defining different phases of the cell cycle through DNA 
content might be problematic and is partly avoided using the FlowJo mathematical 
algorithms. 
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4 RESULTS 
4.1 PAPER I 
The apoptosis signaling in the epithelioid STAV-AB and sarcomatoid STAV-FCS cells 
was evaluated after 24 hours of 10 μM selenite treatment. At this time point around 
15% of cells from both phenotypes were in late apoptosis or undergoing necrosis. The 
proportion of early apoptotic cells was also increased, yielding a decrease of the total 
amount of viable cells. The sarcomatoid cells were especially affected by selenite 
treatment. A 3-fold loss in mitochondrial membrane potential was induced in both cell 
lines measured with the JC-1 probe and verified with 3,3-dihexyloxacarbocyanine 
iodide staining.  
 
Inhibiting p38 did not affect the ability of selenite to induce apoptosis in the epithelioid 
cells. In the sarcomatoid cells a small decrease in the apoptotic response was seen and 
in both cell types, inhibiting p38 caused a decrease in the mitochondrial membrane 
potential after selenite treatment. Inhibiting c-Jun N-terminal kinase (JNK) in selenite 
treated cells increased the amount of early apoptotic epithelial cells while no change in 
the effect was seen in sarcomatoid cells. Both cell lines responded to selenite with a 
time dependent increase of nuclear p53 immunoreactivity but the binding of p53 to 
DNA was decreased. The p21 expression is regulated by p53 and the small fraction of 
p21 positive cells in untreated cells was approximately doubled by selenite treatment. 
Inhibition of p53 did not result in a decrease of apoptosis frequency or loss of 
mitochondrial membrane potential.  
 
Selenite induced Bax expression in the sarcomatoid cells but not in the epithelioid cells. 
The Bcl-XL expression decreased in epithelioid cells after selenite treatment and in a 
subpopulation of sarcomatoid cells. Both cell lines showed a large increase in caspase-
mediated cleavage of cytokeratin 18 after selenite treatment. Baseline expression of 
procaspase-3 was similar in both phenotypes and after selenite treatment a loss of 
procaspase-3 was seen in subpopulations of both cell lines. Pretreatment with cathepsin 
B inhibitor caused slight changes in apoptotic rate and viability after selenite exposure 
and an increased loss of mitochondrial membrane potential. Inhibiting cathepsin D and 
E did not affect the mitochondrial membrane potential nor the apoptosis induced by 
selenite. Autophagy was not seen in cell lines after selenite treatment.  
 
4.2 PAPER II 
We compared the gene expression in tumor cells from a patient with malignant 
mesothelioma before and after developing resistance to pemetrexed and carboplatin 
treatment. This revealed 241 overexpressed and 289 down-regulated genes in the post 
resistant samples. The group of genes involved in metabolic process of nucleobase, 
nucleoside, nucleotide and nucleic acid were the most overexpressed genes. Negative 
regulators of the same process were down-regulated together with genes involved in 
cell communication.  
 
The cell membrane EMA staining increased from 40% to 70% in the acquired 
resistance tumor cells compared to the original tumor. Reactivity of checkpoint kinase 
1 and TS increased from no detectable staining to 50% and 25% of the tumor cells, 
respectively. Both the gene and the protein of cytokeratin 7 and thymidine 
phosphorylase were significantly overexpressed at resistance compared to the original 
tumor.  
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The NT5C gene codes for a protein that was indicated as a central protein in the 
development of resistance but when partly silencing the expression in M-14-K and ZL-
34 cells, no significant differences were seen in response to pemetrexed treatment. 
However, we could see some minor differences in pemetrexed treated ZL-34 cells, with 
more live cells after NT5C silencing and changes in the cell cycle distribution, 
compared to pemetrexed treated control cells.  
 
Serum CYFRA 21-1 was below cut-off levels at diagnosis and the value then increased 
2-fold above cut-off at resistance. Serum mesothelin related protein in the original 
sample was increased 12-fold compared to the normal value, then decreased and 
increased again after resistance to treatment. Carcinoma antigen 125 followed a similar 
course, with high levels at diagnosis and at resistance. This indicates a potential of the 
two proteins to monitor the treatment progress in patients with malignant pleural 
mesothelioma. 
 
4.3 PAPER III 
We characterized six mesothelioma cell lines and observed considerable variations in 
their doubling time. Based on this and the displayed morphological heterogeneity, one 
cell line was considered as epithelioid, one as sarcomatoid and four cell lines as 
biphasic.  
 
When evaluating the cytotoxicity of single drugs, selenite affected the epithelioid 
STAV-AB cells and the biphasic M-14-K, ZL-34 and STAV-FCS cells. Bortezomib 
affected two cell lines, while doxorubicin only affected one. Gemcitabine and 
carboplatin showed effects on two different cell lines. Pemetrexed was the least 
effective single drug when measured using WST-1. When staining treated cells with PI, 
we could see statistically significant effects on the viability in three cell lines and 
observe an early S-phase arrest. This arrest was also seen in the ZL-34 cells but the two 
cell lines with the highest length/width ratios, JL-1 and DM-3 cells, remained 
unaffected.  
 
Selenite combined with bortezomib was the most potent combination in this study, 
affecting all six cell lines. The remaining combinations with selenite also had strong 
effects but the JL-1 and DM-3 remained unaffected. Drug combinations with 
bortezomib strongly affected some of the cell lines, especially in combination with 
carboplatin when effects were seen on all cell lines besides STAV-FCS. No general 
synergistic or antagonistic patterns could be demonstrated, even though doxorubicin 
showed statistically significant synergism in combination with other drugs. When 
combinations the conventional drugs doxorubicin and carboplatin was the most 
effective combination with effects on STAV-AB, M-14-K and ZL-34 cells. MRP-1 
immunoreactivity predicted the sensitivity of the cell lines to treatment with carboplatin 
and presence of xCT predicted pemetrexed effect.  
 
4.4 PAPER IV 
Primary cells from patients with malignant mesothelioma display a large variability in 
their ex vivo chemosensitivity, comparing the different cell cultures. Actinomycin D 
and daunorubicin affected more than ten of the 18 malignant isolates, and taxanes, 
vinca alkaloids and anthracyclines were the most potent groups of drugs. The four most 
resistant cell isolates were affected by one drug and the four most sensitive by ten 
drugs.  
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The proportion of malignant cells in the primary cell isolates inversely correlated to the 
proportion of effective drugs and a trend towards correlation with overall survival of 
the patients was observed. The survival time correlated to the drug sensitivity estimated 
from the number of effective drugs but not to the drug efficiency. Separating samples 
into two groups according to proportion of malignant cells in a Kaplan-Meier analysis 
showed a longer survival time for patients with less than 45% malignant cells. 
Adjusting drug efficiency for pemetrexed, cisplatin and doxorubicin treatment 
increased the correlation with survival.  
 
Immunocytochemical reactivity of RRM1 was correlated to the number of effective 
drugs and primary cell cultures were more resistant to antimicrotubule agents with a 
higher reactivity for RRM1. Cytoplasmatic staining for this epitope was stronger and 
number of effective drugs was lower in the group with the more than 45% malignant 
cells. Dividing the cell isolates into two groups according to their drug sensitivity 
showed that the proportion of malignant cells and RRM1 staining was lower and 
weaker in the group with the sensitivity samples. The number of malignant cells and 
RRM1 staining increased over time when looking at four isolates from the same 
patient.  
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5 DISCUSSION 
Chemotherapy is the main therapeutic option in malignant pleural mesothelioma, 
however with limited benefits. The standard treatment, combining pemetrexed and 
cisplatin, only yields a response rate of around 40%
302
. This response rate correlates to 
the overall survival and tumor phenotype
106-108,127
. Since such treatment is associated 
with both considerable side effects and cost, it would be beneficial to identify 
responders and non-responders before treatment is initiated. For this purpose the 
development of methods and markers predicting the response becomes increasingly 
important. A greater and more detailed understanding of tumor characteristics, new 
drugs and drug combinations based on individual tumor features, can also hopefully 
improve outcome for malignant pleural mesothelioma patients. 
 
In this thesis cell lines and primary cells from patients with malignant mesothelioma 
were used. Their drug sensitivity and the expression of different potential predictive 
markers were studied. The mechanisms for selenite and pemetrexed induced apoptosis 
and resistance development to pemetrexed treatment in patients were further evaluated. 
 
The drug sensitivity of six malignant mesothelioma cell lines was presented in paper 
III. Selenite was the most potent drug but the two cell lines with the most sarcomatoid 
phenotypes, measured as highest length/width ratio, were unaffected. Drug 
combinations with selenite had powerful cytotoxic effects in all tested cell lines. The 
cytotoxic effect of selenite is mainly through oxidizing free thiols, generating reactive 
oxygen species and inducing oxidative stress
105
. This is controlled by the cellular 
uptake of selenite and an increased expression of xCT and MRP-1 increases the effect 
of selenite
279
. Immunocytochemical demonstrations of xCT and MRP-1 did however 
not predict the sensitivity of the six cell lines in paper III.  
 
Results in paper I demonstrate that apoptosis observed in malignant mesothelioma cell 
lines after selenite treatment are the result of a complex mechanism. Selenite treatment 
induces p38 and JNK activation and decreases the mitochondrial membrane potential. 
At the same time p53 accumulation in the nucleus but does not bind to DNA. This 
might be due to changes in the redox system with more reactive oxygen species and 
suppressed activity of the thioredoxin system. A tumor dominated by sarcomatoid 
mesothelioma cells has a poor prognosis and this is also reflected by the 
chemoresistance of the STAV-FCS cell line, which seem to be biphasic with a 
dominating sarcomatoid component. Selenite has however, a stronger effect on the 
STAV-FCS than the epithelioid STAV-AB cells and this might partly be due to higher 
levels of proapoptotic mediator Bax in the STAV-FCS cells, while the lower sensitivity 
of the epithelioid cells might be due to down-regulation of Bcl-XL. As seen in paper 
III, this sensitivity to selenite is not general among the sarcomatoid mesothelioma cell 
lines.  
 
Bortezomib treatment affected three of the cell lines in paper III and this effect was 
increased when combining with the conventional drugs. Bortezomib targets the 20S P 
subunit of the proteasome and is used in treatment of multiple myeloma but has not 
been effective in clinical trials with malignant mesothelioma patients
254,256
. The six cell 
lines were generally unaffected by treatment with doxorubicin, gemcitabine or 
carboplatin, but in different combinations, however, significant synergistic effects were 
induced by doxorubicin. This mirrors the clinical situation were treatment with a single 
drug is ineffective and drug combinations yield better results.  
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The limitations of using the WST-1 reaction to monitor drug effects were obvious when 
treating cell lines with pemetrexed (paper III). The WST-1 analysis could not detect 
any response, while staining cells with PI presented extensive effects with s-phase 
arrest in the three cell lines with the lowest length/width ratios. When using VitalDye to 
identifying live and dead cells (paper IV), pemetrexed did not show any effect. The 
variability between the outcomes of pemetrexed treatment when using the three 
different experimental settings can be explained by measurement of different cellular 
responses. Pemetrexed seems to induce cell cycle arrest and increased metabolic 
activity in the cell population, highlighting the need to study several aspects of cell 
viability.  
 
To our knowledge, paper II is the first published where the gene expression at the time 
of diagnosis of a malignant mesothelioma is compared to that after developing 
resistance towards pemetrexed and carboplatin treatment. Our results indicate that 
changes in the metabolism of pyrimidine and purine are central in this development of 
resistance. The value of measuring TS protein expression and not mRNA in response to 
treatment was seen in these experiments. The NT5C gene was overexpressed, encoding 
a protein involved in the metabolism of purines. Silencing the gene has previously been 
shown to induce drug sensitivity but this was not the case in our experiments
352
. This 
might be because the protein coded for by the NT5C gene was still active; effect of 
silencing was not measured on protein level.  
 
Checkpoint kinase 1 is important in the G2/M checkpoint as well as DNA repair and 
has been identified as a target for sensitizing cells to treatment with different drugs
353-
355
. The importance of the protein was verified in our study with higher 
immunoreactivity in the resistant tumor. The increase in EMA and cytokeratin 7 at 
resistance might serve as a resistance marker, while levels of the remaining routinely 
used immunohistochemical diagnostic markers such as calretinin and EpCam were not 
altered and do not seem to be involved in the changed biology of the tumor. The levels 
of genes encoding for serum mesothelin related protein and carcinoma antigen 125 
were not increased in the resistant samples, indicating that the increased amount of 
these proteins in serum would rather reflect an increased tumor burden. Therefore, the 
levels of the two proteins function as markers for disease progression but are not 
involved in the resistance.  
 
Large variability in the sensitivity to different drugs and a broad resistance was 
observed in paper IV, reflecting the clinical situation with limited effect of 
chemotherapy and a scattered response rate. The proportion of malignant cells in the 
pleural effusions is crucial for the ability to estimate sensitivity in this experimental set-
up, correlating to the proportion of effective drugs. There was also a trend towards 
correlations of this parameter to the survival time of patient. When the drug effect was 
adjusted according to proportion of malignant cells and theoretical effect on benign 
cells, the cell isolates with lower proportions were still affected by a higher proportion 
of drugs. This indicates that malignant mesothelioma patients with higher proportions 
of malignant cells have a more advanced disease, with drug resistance and shorter 
survival time.  
 
RRM1 reactivity in the primary cell isolate seems to be important for drug sensitivity 
and survival of the patient. The ability of RRM1 reactivity to predict the effects of 
drugs has previously been shown in non-small cell lung cancer patients treated with 
cisplatin and vinorelbine
356
. In repeated pleural effusions from the same patient we 
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observed a progressed disease with an increased proportion of malignant cells, RRM1 
reactivity and drug resistance. 
 
Adjusting the drug effect to admixture of benign cells and the theoretical effect on the 
benign cells increased the correlation to survival time, especially for pemetrexed and 
cisplatin. Interestingly, after this adjustment, cell isolates not affected by pemetrexed 
and cisplatin were affected by drugs such as carboplatin, doxorubicin and gemcitabine, 
used in other drug combinations recently described for patients with malignant 
mesothelioma
312
. This indicates that these patients might have responded better to 
alternative drug combinations as first line treatment. This motivates a further 
development of ex vivo testing of drug sensitivity as basis for personalized choice of 
treatment.  
 
5.1 CONCLUSIONS 
In this thesis it is concluded that there is a need for individualized treatment of 
malignant mesothelioma patients. This can to a certain extent be based on results from 
studying tumor cells from their pleural effusion, optimizing the choice of drug 
combinations. 
 
Selenite is a potent cytotoxic agent in malignant mesothelioma cell lines by inducing 
apoptosis in a complex and phenotype dependent manner. The apoptosis signaling 
caused by selenite is described and partly explained.  
 
Several different genes coding for TS and proteins involved in the metabolic processes 
of pyrimidine and purine, are involved in resistance development to pemetrexed and 
carboplatin treatment in a patient. We suggest that EMA and cytokeratin 7 levels can be 
used as potential resistance markers and that tumor progression might be followed by 
levels of serum mesothelin related protein and carcinoma antigen 125. 
 
We observed heterogeneity in the six mesothelioma cell lines with different 
morphology, variable drug sensitivity and different expression of predictive markers. 
Selenite and bortezomib were more effective than the conventional drugs and arrest in 
S-phase was seen in cell lines treated with pemetrexed.  
 
When studying primary cell isolates from patients with malignant mesothelioma we 
observed a large variability in their drug sensitivity which seems to correlate to 
proportion of malignant cells and RRM1 reactivity. The observed sensitivity should be 
corrected for the theoretical drug effect on benign cells and admixture of benign cells.  
 
5.2 FUTURE PERSPECTIVES 
The results in this thesis indicate the need and possible approaches to individualized 
treatment of malignant mesothelioma patients. We hypothesize that by studying the 
drug sensitivity of primary tumor cells the optimal treatment strategy for each 
individual patient might be predicted, measuring the tumor specific cell death. Focus 
should then, preferably, be directed towards the in vitro effects of drugs that previously 
have been evaluated in treatment of malignant mesothelioma and therefore are accepted 
as alternative treatment options. The use of predictive markers can also be of help, 
although the arsenal can be improved. By performing such more detailed studies we 
might be able to suggest both the best first line treatment and the best alternative in 
patients that are not responding.  
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Difficulties in evaluating primary cultures due to admixture of variable amounts and 
types of benign cells should also be addressed. One possibility is to use flow cytometry. 
Such an analysis can be developed to include not only markers for apoptosis and cell 
cycle arrest, but also different proteins essential to drug resistance. Over time such 
studies may also help to better explain and understand resistance development in 
patients. 
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